Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
28
3
2020
medline:
28
3
2020
entrez:
28
3
2020
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disease, and accounts for a substantial proportion of unplanned hospital admissions. Care bundles for COPD are a set of standardised, evidence-based interventions that may improve outcomes in hospitalised COPD patients. We estimated the cost effectiveness of care bundles for acute exacerbations of COPD using routinely collected observational data. Data were collected from implementation (n = 7) and comparator (n = 7) acute hospitals located in England and Wales. We conducted a difference-in-difference cost-effectiveness analysis using a secondary care (i.e. hospital) perspective to examine the effect on National Health Service (NHS) costs and 90-day mortality of implementing care bundles compared with usual care for patients admitted to hospital with an acute exacerbation of COPD. Adjusted models included as covariates patient age, sex, deprivation, ethnicity and seasonal effects and mixed effects for site. Outcomes and baseline characteristics of up to 12,532 patients were analysed using both complete case and multiply imputed models. Implementation of bundles varied. COPD care bundles were associated with slightly lower secondary care costs, but there was no evidence that they improved outcomes once adjustments were made for site and baseline covariates. Care bundles were unlikely to be cost effective for the NHS with an estimated net monetary benefit per 90-day death avoided from an adjusted multiply imputed model of -£1231 (95% confidence interval - £2428 to - £35) at a high cost-effectiveness threshold of £50,000 per 90-day death avoided. Care bundles for COPD did not appear to be cost effective, although this finding may have been influenced by unmeasured variations in bundle implementation and other potential confounding factors.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disease, and accounts for a substantial proportion of unplanned hospital admissions. Care bundles for COPD are a set of standardised, evidence-based interventions that may improve outcomes in hospitalised COPD patients. We estimated the cost effectiveness of care bundles for acute exacerbations of COPD using routinely collected observational data.
METHODS
METHODS
Data were collected from implementation (n = 7) and comparator (n = 7) acute hospitals located in England and Wales. We conducted a difference-in-difference cost-effectiveness analysis using a secondary care (i.e. hospital) perspective to examine the effect on National Health Service (NHS) costs and 90-day mortality of implementing care bundles compared with usual care for patients admitted to hospital with an acute exacerbation of COPD. Adjusted models included as covariates patient age, sex, deprivation, ethnicity and seasonal effects and mixed effects for site.
RESULTS
RESULTS
Outcomes and baseline characteristics of up to 12,532 patients were analysed using both complete case and multiply imputed models. Implementation of bundles varied. COPD care bundles were associated with slightly lower secondary care costs, but there was no evidence that they improved outcomes once adjustments were made for site and baseline covariates. Care bundles were unlikely to be cost effective for the NHS with an estimated net monetary benefit per 90-day death avoided from an adjusted multiply imputed model of -£1231 (95% confidence interval - £2428 to - £35) at a high cost-effectiveness threshold of £50,000 per 90-day death avoided.
CONCLUSION AND RECOMMENDATIONS
CONCLUSIONS
Care bundles for COPD did not appear to be cost effective, although this finding may have been influenced by unmeasured variations in bundle implementation and other potential confounding factors.
Identifiants
pubmed: 32215856
doi: 10.1007/s41669-020-00207-w
pii: 10.1007/s41669-020-00207-w
pmc: PMC7688870
doi:
Types de publication
Journal Article
Langues
eng
Pagination
657-667Subventions
Organisme : Department of Health
ID : 12/130/53
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P014259/1
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : 12/130/53
Références
BMJ. 2017 Jan 31;356:j557
pubmed: 28148489
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Health Econ. 2013 Apr;22(4):486-500
pubmed: 22447531
BMJ Open Respir Res. 2019 May 30;6(1):e000425
pubmed: 31258918
BMC Pulm Med. 2016 Feb 25;16:35
pubmed: 26916196
Pharmacoeconomics. 2014 Dec;32(12):1157-70
pubmed: 25069632
Health Econ. 2002 Jul;11(5):415-30
pubmed: 12112491
Pharmacoeconomics. 2017 Jan;35(1):43-63
pubmed: 27592021